Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC plus durvalumab for unresectable or regionally recurrent perihilar cholangiocarcinoma
ChiCTR2500096118Phase 2Recruiting
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Jan 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, oxaliplatin, folinic acid and fluorouracil in hilar cholangiocarcinoma (HC), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoint: Objective Response Rate. Started Jan 2025; status: recruiting.
02
Drugs
durvalumaboxaliplatinfolinic acidfluorouracil
03
Conditions
hilar cholangiocarcinoma (HC)
Beyond the preview
Go deeper on ChiCTR2500096118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096118.